

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-43. (Withdrawn)

44. (Currently Amended) A double-stranded molecule comprising a sense strand and an antisense strand, wherein the sense strand comprises a ribonucleotide sequence corresponding to a KIF11, ~~GHSR1b, NTSR1 or FOXM1~~ target sequence, and wherein the antisense strand comprises a ribonucleotide sequence which is complementary to said sense strand, wherein said sense strand and said antisense strand hybridize to each other to form said double-stranded molecule, and wherein said double-stranded molecule, when introduced into a cell expressing a KIF11, ~~GHSR1b, NTSR1 or FOXM1~~ gene, inhibits expression of said gene, wherein said KIF11 target sequence comprises a nucleotide sequence of SEQ ID NO: 34.

45. (Cancelled)

46. (Currently Amended) The double-stranded molecule of claim ~~[[45]]~~44, wherein said KIF11, ~~GHSR1b, NTSR1 or FOXM1~~ target sequence ~~comprises is from about 19 to about 25 contiguous nucleotides from the nucleotide sequences selected from the group of~~ SEQ ID NOs: 1, 3, 5, and ~~106~~ NO: 1.

47. (Currently Amended) The double-stranded molecule of claim 46, wherein said KIF11, ~~GHSR1b, NTSR1 or FOXM1~~ target sequence is ~~selected from the group consisting of~~ SEQ ID NOs: 32, 33, 34, 35, 36, 37, and ~~108~~ NO: 34.

48. (Original) The double-stranded molecule of claim 44, wherein said double-stranded molecule is a single ribonucleotide transcript comprising the sense strand and the antisense strand linked via a single-stranded ribonucleotide sequence.

49-53. (Cancelled)

54. (Currently Amended) A vector encoding the double-stranded molecule of claims 44, 46 or 47.

55. (Original) The vector of claim 54, wherein the vector encodes a transcript having a secondary structure and comprises the sense strand and the antisense strand.

56. (Original) The vector of claim 55, wherein the transcript further comprises a single-stranded ribonucleotide sequence linking said sense strand and said antisense strand.

57. (Currently Amended) A vector comprising a polynucleotide comprising a combination of a sense strand nucleic acid and an antisense strand nucleic acid, wherein said sense strand nucleic acid comprises nucleotide sequence ~~selected from the group consisting of~~ SEQ ID NOs: 32, 33, 34, 35, 36, 37, and 108-NO: 34, and said antisense strand nucleic acid consists of a sequence complementary to the sense strand, wherein said sense strand and said antisense strand hybridize to each other to form said double-stranded molecule, and wherein said double-stranded molecule, when introduced into a cell expressing a KIF11 gene, inhibits expression of said gene.

58. (Currently Amended) The vector of claim 57, wherein said polynucleotide has the general formula



wherein [A] is a nucleotide sequence selected from the group consisting of SEQ ID NOs: 32, 33, 34, 35, 36, 37, and 108-NO: 34; [B] is a nucleotide sequence consisting of 3 to 23 nucleotides; and [A'] is a nucleotide sequence complementary to [A].

59. (Cancelled)

60. (Currently Amended) A composition for treating or preventing NSCLC, said composition comprising a pharmaceutically effective amount of an siRNA against a gene

selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1, wherein the siRNA comprises a sense strand and an antisense strand, wherein the sense strand comprises a ribonucleotide sequence corresponding to a KIF11 target sequence, and wherein the antisense strand comprises a ribonucleotide sequence which is complementary to said sense strand, wherein said sense strand and said antisense strand hybridize to each other to form said siRNA, and wherein said siRNA, when introduced into a cell expressing a KIF11 gene, inhibits expression of said gene, wherein said KIF11 target sequence comprises a nucleotide sequence of SEQ ID NO:34.

61. (Currently Amended) The composition of claim 60, wherein the siRNA comprises a sense strand comprising the nucleotide sequence of SEQ ID NO: 32, 33, 34, 35, 36, 37, and 108NO: 34, as the target sequence.

62-68. (Withdrawn)

69. (New) The composition of claim 60, wherein the target sequence is from 19 to 25 contiguous nucleotides from the nucleotide sequence of SEQ ID NO:1.